amino acid · for chronic inflammation
N-Acetyl Cysteine
Raw material for your body’s main antioxidant, which quietens inflammatory signalling.
Say that in clinical terms
NAC is the rate-limiting precursor for glutathione synthesis, the body's primary endogenous antioxidant. It directly inhibits NF-kB activation, reduces oxidative stress-driven inflammatory cascades, and decreases CRP, IL-6, and TNF-alpha levels.
How strong is the research?
1 paper read, 1 supporting.
Who was studied: The cited review covers ALS, Alzheimer’s, Parkinson’s and psychiatric illness — not everyday inflammation.
How much to take
daily (split doses)
600–1800 mg
NAC replenishes glutathione, the master antioxidant. Take on empty stomach. Start at 600mg and increase.
Before you take it
- No IOM/NIH ODS Tolerable Upper Intake Level established for NAC as a dietary supplement (not an essential nutrient); adverse effects are dose-dependent and increase above 1,200 mg/day.
- Potentiates organic nitrate drugs (nitroglycerin, isosorbide dinitrate) — severe hypotension documented in cardiology settings; avoid co-administration.
- Additive anticoagulant effect with warfarin (INR monitoring required); additive antiplatelet effect with aspirin.
- Antibiotic separation required: administer NAC at least 2 hours before or 4–6 hours after tetracyclines and quinolones to prevent chelation-mediated reduction in antibiotic absorption.
- GI side effects (nausea, vomiting, diarrhea) are dose-dependent; most common at oral doses above 1,200 mg/day.
- FDA drug-exclusion position (2020): FDA classified NAC as excluded from the dietary supplement definition because it was authorized as a new drug in 1963 (Mucomyst/acetylcysteine). As of 2022, FDA exercised enforcement discretion allowing existing NAC supplements on market; no final rule published as of 2025, leaving US supplement regulatory status unsettled.
- Rare anaphylactoid reactions with IV formulations; bronchospasm with inhaled/nebulized forms; both are uncommon via oral supplementation route.
What we make of it
The paper we cite is about neurological disease, and most of what it covers is animal and cell work.
The detail
The citation is a review of how NAC behaves in neurological conditions, not a pooled analysis and not about inflammation in the body generally. What it summarises is mostly animal and cell-culture research. The citation needs replacing with a proper analysis of inflammation markers in people.